Please login to the form below

Not currently logged in
Email:
Password:

Antares CEO Wotton resigns

He will move to Advanced Cell Technology

antares paul wottonAntares Pharma CEO Paul Wotton is to resign his position to take over as CEO at development-stage biotech company Advanced Cell Technology.

Wotton spent nearly six years in charge of New Jersey-based Antares, having previously served as CEO of Topigen Pharmaceutical.

His replacement at Antares is Eamonn Hobbs, a current board member of the company.  He has over 30 years of experience in the pharma and medical device sectors.

Hobbs was most recently president and CEO of Delcath Systems, a pharma and medical device company specialising in cancer treatment.

“We have worked closely with Eamonn over the past five years as board members and share his vision for the future,” said Leonard Jacob, chairman of the board of directors.

2nd July 2014

From: Research, Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cello Health

Cello Health’s mission is to help our clients unlock the potential that exists with their assets, brands and organisations in...

Latest intelligence

Brain power: fresh approaches to Alzheimer’s drug discovery
New alliances are learning from past mistakes and breaking down research barriers...
Genomics integration: can the NHS rise to the challenge?
Experts gather to discuss the UK’s genomic landscape...
London
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...

Infographics